PATENT CLAIM ANALYSIS

Application Number: 16025832
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "006200"]

Abstract:
A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, includes at least a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and a dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals. Single-dose formulations at a pH of between 7 and 7.8 includes a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin.

Claim (Index 13):
The composition according to  claim 1 , wherein the dextran polymers substituted by radicals carrying carboxylate charges and hydrophobic radicals is chosen from the group consisting of the dextran polymers of formula II and is:\n Sodium dextranmethylcarboxylate modified by cholesteryl 1-ethylenediaminecarboxylate grafted by reductive amination to the reducing chain end.

Metadata:
- Claim Count in Document: 68.0
- Percentile: 95.0
- Lexical Diversity: 1.77778
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13571026', '15899795', '15616470', '15616128', '14922663']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8572135683006318
- 35 USC 102 Novelty (BERT): 0.7121280088456516
- Combined Prediction Score: 0.8427050123551337
- Mean Citation Score: 575.206164
- Max Citation Score: 816.0116
- Similarity Product: 756.645027697134

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test